3-Methylbutyrfentanyl
Opioid analgesic
- CA: Schedule I
- DE: NpSG (Industrial and scientific use only)
- UK: Class A
- US: Schedule I[1]
- N-[3-Methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylbutanamide
- 97605-09-9
- 86130531
- 57434313
- 875L53T89N
- DTXSID501017180
- Interactive image
- CCCC(=O)N(c1ccccc1)C2CCN(CC2C)CCc3ccccc3
InChI
- InChI=1S/C24H32N2O/c1-3-10-24(27)26(22-13-8-5-9-14-22)23-16-18-25(19-20(23)2)17-15-21-11-6-4-7-12-21/h4-9,11-14,20,23H,3,10,15-19H2,1-2
- Key:ZPAOSKLOFZWBLS-UHFFFAOYSA-N
3-Methylbutyrfentanyl (3-MBF) is an opioid analgesic that is an analog of butyrfentanyl.[2][3][4][5]
Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[6]
See also
- 3-Methylfentanyl
- 4-Fluorobutyrfentanyl
- 4-Fluorofentanyl
- α-Methylfentanyl
- Acetylfentanyl
- Furanylfentanyl
- List of fentanyl analogues
References
- ^ Drug Enforcement Administration, Department of Justice (February 2018). "Schedules of Controlled Substances:Temporary Placement of Fentanyl-Related Substances in Schedule I. Temporary amendment; temporary scheduling order". Federal Register. 83 (25): 5188–92. PMID 29932611.
- ^ Higashikawa Y, Suzuki S (June 2008). "Studies on 1-(2-phenethyl)-4-(N -propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues". Forensic Toxicology. 26 (5): 1–5. doi:10.1007/s11419-007-0039-1. S2CID 22092512.
- ^ Vardanyan RS, Hruby VJ (March 2014). "Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications". Future Medicinal Chemistry. 6 (4): 385–412. doi:10.4155/fmc.13.215. PMC 4137794. PMID 24635521.
- ^ Jin WQ, Xu H, Zhu YC, Fang SN, Xia XL, Huang ZM, et al. (May 1981). "Studies on synthesis and relationship between analgesic activity and receptor affinity for 3-methyl fentanyl derivatives". Scientia Sinica. 24 (5): 710–20. PMID 6264594.
- ^ Huang ZM, Zhou J, Chen XJ, Zheng WJ, Zhang HP, Chi ZQ, et al. (September 1984). "[Analgesic activity and toxicity of potent analgesics, ohmefentanyl and mefentanyl]". Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica. 5 (3): 153–8. PMID 6239505.
- ^ Mounteney J, Giraudon I, Denissov G, Griffiths P (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". The International Journal on Drug Policy. 26 (7): 626–31. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.
- v
- t
- e
(MOR)
(DOR)
(KOR)
(NOP)
Agonists |
|
---|---|
Antagonists |
|
- Enkephalinase inhibitors: Amastatin
- BL-2401
- Candoxatril
- D -Phenylalanine
- Dexecadotril (retorphan)
- Ecadotril (sinorphan)
- Kelatorphan
- Racecadotril (acetorphan)
- RB-101
- RB-120
- RB-3007
- Opiorphan
- Selank
- Semax
- Spinorphin
- Thiorphan
- Tynorphin
- Ubenimex (bestatin)
- Propeptides: β-Lipotropin (proendorphin)
- Prodynorphin
- Proenkephalin
- Pronociceptin
- Proopiomelanocortin (POMC)
- Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer)
![]() | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e